Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

By S. Rajkumar, Robert A. Kyle, Terry M. Therneau, L. Melton, A. Bradwell, R. Clark, Dirk R. Larson, M. Plevak, A. Dispenzieri, J. Katzmann. Blood, 2005

682 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/baa7c8404da8851f717648bc5627d815f0548bfb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar
2. Andreas Hochhaus

In Molecular Biology

1. S. Rajkumar
2. Aliyah R. Sohani
3. P. Richardson

Citations in the corpus

• International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009, background): “(Rajkumar SV et al.(17) Serum-free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.”
• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (2010, background): “The FLC ratio was independent of the size and type of serum monoclonal protein (16).”
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (2022, background): “5 g/dL is considered high risk with approximately 50–60% risk of progression at 20 years, whereas the risk is only 5% when none of the risk factors are present [188].”